Site icon OncologyTube

ASCO 2021 Lung Recap: Surgical Outcomes & Checkmate 816: Nivolumab in Early Stage NSCLC

Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021.

For this series, the doctors discuss new trials for patients with NSCLC. The doctors discuss CheckMate 816, the addition of Nivolumab as neoadjuvant therapy in Early Stage NSCLC.

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Exit mobile version